Cargando…
Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism
PURPOSE: Recent clinical trials showed that the sequential combination of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy could prolong the PFS and/or OS of advanced non-small cell lung cancer (NSCLC) patients with EGFR mutation. The aim of present study was...
Autores principales: | Chen, Bei, Zheng, Jingxian, Zeng, Yunyun, Li, Baofeng, Xie, Bo, Zheng, Jihua, Zhou, Juan, Zhang, Weimin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256223/ https://www.ncbi.nlm.nih.gov/pubmed/25474307 http://dx.doi.org/10.1371/journal.pone.0114074 |
Ejemplares similares
-
Synergism Antiproliferative Effects of Apigenin and Naringenin in NSCLC Cells
por: Liu, Xiongxiong, et al.
Publicado: (2023) -
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
por: Tiseo, M, et al.
Publicado: (2010) -
Gefitinib versus Docetaxel in Treated Non-small-cell Lung Cancer: A Meta-analysis
por: Wang, Bing, et al.
Publicado: (2017) -
Combined treatment with N‐acetylcysteine and gefitinib overcomes drug resistance to gefitinib in NSCLC cell line
por: Li, Jun, et al.
Publicado: (2019) -
Inhibition of DNA-PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC
por: Pan, Chi, et al.
Publicado: (2020)